Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.

Also called NCT05701956

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 330 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05701956
Other papers using this trial's data
  • Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion: The ATTENTION LATE Randomized Clinical Trial JAMA, 2026-11-03 DOI, PubMed 42776543, PMC13602079 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05701956. Randomized; single masking; primary purpose treatment. Start 2023-03-16 (actual); primary completion 2025-02-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion
Condition
Basilar Artery Occlusion
Condition
Acute Cerebrovascular Accident
Condition
Stroke Due to Basilar Artery Occlusion
Intervention (Drug)
Tenecteplase
Intervention (Procedure)
Endovascular thrombectomy
Lead sponsor
The First Affiliated Hospital of University of Science and Technology of China (class: other)

Record details

Record id
cardio:ct-nct05701956
Content hash
b602bf9788def74848383fe77de39639db8bcdb927d636d65e813d1bcdb1835a